Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

NCT00055861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: docetaxel
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)